Atlas Trials

Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.

Clinical trial NCT02554851 · UNKNOWN

Trial details

NCT number
NCT02554851
Sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Foot Ulcer, DiabeticEpidermal Growth Factor
Start date
2017-01-01
Primary completion
2019-12-01
Enrollment
304

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.